A Study to Investigate Subcutaneous Isatuximab in Combination With Weekly Carfilzomib and Dexamethasone in Adult Participants With Relapsed and/or Refractory Multiple Myeloma
← catalyst calendarNCT06356571 · readout in 141 d
Sponsored by Sanofi (industry) · SNY — their whole pipeline →.
Phase
Phase 2
Status
Recruiting
Study type
Interventional
Design
Na · None · Treatment
Enrollment
64estimated
Sites
34
Country
United States
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2025-03-17 | actual | When the study began enrolling |
| Primary completion | 2027-01-08 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2027-07-15 | estimated | The whole study's end, after follow-up |
| First posted | 2024-04-10 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-02-23 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Plasma Cell Myeloma Refractory
Interventions
- Drug: Isatuximab SC-OBDS — also filed as SAR650984, Sarclisa
- Drug: Montelukast
- Drug: Dexamethasone
- Drug: Acetaminophen
- Drug: Diphenhydramine
- Drug: Methylprednisolone
- Drug: Carfilzomib
Primary outcome
what the primary-completion date above is the date OFOverall response rate (ORR)
measured 6 months after the Last Participant In (LPI) i.e., approximately 32 months
Permalink · SNY's whole pipeline · Catalyst calendar · Every registered study · What changed